US Stock Market Move | The previously announced weight loss drug Cagrisema data caused Novo Nordisk A/S Sponsored ADR Class B (NVO.US) to fall more than 8%.

10/03/2025

GMT Eight

On Monday, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) opened with a drop of over 8%, at $80.10. In terms of news, data shows that CagriSema from Novo Nordisk A/S Sponsored ADR Class B resulted in a 15.7% weight loss in patients after 68 weeks, compared to the market's expectation of 20%. In comparison, the placebo group only experienced a 3.1% weight loss. Novo Nordisk A/S Sponsored ADR Class B is expected to apply for the first regulatory approval for CagriSema in the first quarter of 2026.

Three directors and executives of Asia Cuanon Technology (603378.SH) plan to reduce their holdings by a total of no more than 4.038 million shares.

During the sharp decline of Bitcoin, Strategy (MSTR.US) boosts stablecoin confidence: issuing $2.1 billion in preferred shares to buy coins.

Contact: contact@gmteight.com

US Stock Market Move | The previously announced weight loss drug Cagrisema data caused Novo Nordisk A/S Sponsored ADR Class B (NVO.US) to fall more than 8%.

RECOMMEND

US Stock Market Move | Mineralys Therapeutics (MLYS.US) surges over 53% with the positive results of the release of hypertension drug research.

US Stock Market Move | Bitcoin fell below the $80,000 threshold and concept stocks plummeted across the board.

US Stock Market Move | In February, the combined revenue decreased by 11.3% month-on-month. Taiwan Semiconductor Manufacturing Co., Ltd. Sponsored ADR (TSM.US) dropped more than 4%.